As the second most common neurodegenerative disorder, Parkinson’s disease primarily impacts individuals over the age of 65. In 2019, more than 8.5 million people were living with the disease, leading to 329,000 deaths. The Asia-Pacific region, particularly China, bears the highest burden, followed by the United States and European countries such as Germany, Italy, and the United Kingdom. Alarmingly, global cases are projected to double by 2030, underscoring the urgent need for effective treatments.
A new report by global full-service clinical Contract Research Organization (CRO) Novotech explores the current landscape of clinical trials and emerging therapies in Parkinson’s disease, shining a light on various recent advances. For example, traditional treatment protocols for Parkinson’s disease have relied heavily on Levodopa to manage motor symptoms, often in combination with COMT or MAO-B inhibitors. Dopamine agonists and anticholinergics have also played roles in patient care. While these treatments offer symptomatic relief, they do not halt disease progression. This limitation has spurred a surge in clinical trials aimed at discovering disease-modifying therapies that address the underlying causes of Parkinson’s.
Advances in clinical trials
According to the report, the biotech and biopharma industries have initiated more than 750 clinical trials targeting Parkinson’s disease worldwide since 2019. The Asia-Pacific region leads this endeavour, driven predominantly by Mainland China. North America follows closely, with the United States making significant contributions. Europe also plays a vital role, with the United Kingdom, Russia, and Spain at the forefront. Notably, European trials excel in patient recruitment through multi-country collaborations, providing broader access and leveraging experienced trial sites. This global effort reflects a unified commitment to advancing Parkinson’s research and developing novel therapies.
The evolving treatment landscape encompasses a diverse range of therapeutic approaches. Established companies such as Abbott and AbbVie are advancing small molecules, medical devices, and ultrasound-based techniques. Phase III trials by Amgen and BeiGene are focusing on small molecules and proteins, while early-stage research explores innovative strategies such as cell and stem cell therapies and adeno-associated virus (AAV)-based treatments.
Innovative strategies are also targeting core mechanisms of Parkinson’s disease, such as alpha-synuclein buildup and neuroinflammation. Gene therapies aim to correct genetic mutations, while advanced Deep Brain Stimulation (DBS) techniques offer personalised symptom management. Stem cell and neural progenitor therapies hold potential for regenerating dopamine neurons, and emerging treatments like fecal microbiota transplantation (FMT) target gut health to reduce systemic inflammation. Collectively, these advancements demonstrate a global commitment to revolutionising Parkinson’s disease treatment and enhancing the quality of life for patients worldwide.
Expertise in the global clinical trial landscape
Novotech, established in 1997, has been instrumental in this arena. Partnering with biotech companies, Novotech accelerates the development of advanced therapeutics across all phases of clinical trials. With experience in more than 5,000 clinical projects, the organisation offers a comprehensive suite of services, including laboratories, Phase I facilities, and regulatory expertise. Novotech’s contributions have been recognised through numerous prestigious awards, such as the Frost & Sullivan 2024 Global Biotech CRO Award and the Asia-Pacific Contract Research Organization Company of the Year Award, which it has received annually since 2006.
For those interested in a deeper understanding of the global clinical trial landscape for Parkinson’s disease, a comprehensive report is available for download. This resource provides critical insights into the trends, opportunities, and challenges in Parkinson’s disease research, serving as a valuable tool for healthcare professionals, researchers, and stakeholders committed to combating this condition.
The fight against Parkinson’s disease is gaining momentum, with global collaborations and innovative research paving the way for groundbreaking treatments. The dedication of organisations like Novotech and the collective efforts of the medical community offer renewed hope for patients and their families, bringing us closer to a future where Parkinson’s disease can be effectively managed, if not cured. Download the report below to find out more.
